Charles Schwab Investment Management Inc. Has $27.43 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Charles Schwab Investment Management Inc. boosted its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 3.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 616,153 shares of the company's stock after acquiring an additional 21,157 shares during the period. Charles Schwab Investment Management Inc. owned 1.33% of Omnicell worth $27,431,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of OMCL. Smartleaf Asset Management LLC increased its stake in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares in the last quarter. First Horizon Advisors Inc. increased its stake in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the period. KBC Group NV boosted its holdings in shares of Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company's stock valued at $92,000 after acquiring an additional 778 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in Omnicell during the 4th quarter valued at $201,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Remove Ads

Omnicell Stock Performance

NASDAQ:OMCL traded down $0.91 during trading hours on Friday, hitting $33.97. 346,324 shares of the company traded hands, compared to its average volume of 498,784. The firm has a 50-day moving average of $39.94 and a 200 day moving average of $42.98. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 125.82, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on OMCL. Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Thursday, March 6th. Benchmark reiterated a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, Wells Fargo & Company cut their target price on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.